Aligos Therapeutics price target lowered to $70 from $75 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aligos Therapeutics (ALGS) to $70 from $75 and keeps a Buy rating on the shares. The firm is ...
HC Wainwright Has Lowered Expectations for Aligos Therapeutics (NASDAQ:ALGS) Stock Price
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) had its price objective cut by equities research analysts at HC Wainwright from $75.00 to $70.00 in a research note issued on Tuesday,Benzinga ...
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
R&D expenses for the year ended December 31, 2024 were $70.3 million, compared with $73.0 million for the same period of 2023. Total R&D employee-related costs reduced by $4.2 million which was ...
Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Monday
Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) is expected to be releasing its earnings data before the market opens on ...
Yahoo Finance4d
Aligos Therapeutics, Inc. (ALGS)
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best ...
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of -78.53% and 51.62%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock ...